Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- ASAN +24.6%, RBRK +23%, AOUT +14.6%, DOCU +12.9%, DOOO +12.3%, ULTA +11.6%, ZUMZ +10.5%, GTLB +10.1% (also appoints new CEO), LULU +8.9% (also authorizes $1.0 bln for repurchases), AGX +7.6%, VEEV +7.1%, WOOF +5.9%, VSCO +4.3%, GCO +4.3%, HPE +1.2%, METC +1.2% (guidance)
Other news:
- HLVX +13.4% (commenced workforce reduction of 28 employees (70% of workforce) to reduce op expenses, COO, CMO, CBO ceased serving in their respective officer positions)
- IPHA +6.9% (Innate Pharma and the Institute for Follicular Lymphoma Innovation announce up to $7.9 mln investment from IFLI to support IPH6501 development in follicular lymphoma)
- BY +5.7% (new repurchase plan)
- BYD +4.2% ($500 mln repurchase plan)
- WRD +3.8% (Uber and WeRide (WRD) launch the first autonomous mobility service in Abu Dhabi)
- JD +3.5% (entered into equity transfer agreement to purchase the remaining equity interest of approximately 36.43% in Kuayue-Express Group at a purchase price of up to RMB6,484 million)
- NCTY +3.2% (Increased Committed Annual Revenue to RMB900 Million and Profit to RMB300 Million from RMB600 and RMB200M Respectively)
- MNOV +2.8% (Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND)
- OB +2.7% (shareholders vote to support Teads acquisition)
- TRN +2.2% (increases dividend)
- RKLB +2.2% (launch window scheduled; entered exchange agreement with a family trust established by Sir Peter Beck, the Company's Founder, President, Chief Executive Officer and Chairman)
- FUFU +2.1% (announces November 2024 production and mining operations update)
- YUMC +2% (announces repurchase plan)
- BTBT +1.8% (November update)
- HUT +1.8% (November update)
- PLTR +1.4% (teams up with Shield AI; Booz Allen Hamilton and Palantir Technologies (PLTR) jointly announced today a groundbreaking co-creation partnership to accelerate defense mission innovation and help the U.S. maintain superiority against its adversaries)
- PACS +1.2% (operating subsidiaries closed on the operations of 11 skilled nursing facilities)
- AZN +1.2% (reports Imfinzi granted Priority Review in the US for patients with muscle-invasive bladder cancer; reports Datopotamab Deruxtecan demonstrated meaningful clinical activity in patients with previously treated advanced EGFR-mutated non-small cell lung cancer)
- SKYT +1.2% (receives proposed CHIPS funding)
- BK +1.1% (files $40 bln mixed shelf)
- UEC +1.1% (Completes Acquisition of Rio Tinto's Sweetwater Plant and Wyoming Uranium Assets)